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Abstract: Due to the involvement of the endocannabinoid system (ECS) in cancer onset and
progression and the less studied connection between ECS and bladder cancer, here an evaluation of
the ECS modifications associated with bladder cancer is reported. Urine samples were collected from
healthy volunteers and patients with bladder cancer at different grades. Endocannabinoids (ECs) and
N-acylethanolamides (NAEs) were quantified by HPLC-MS/MS and results normalized for creatinine
content. An increase in the urine concentrations of four ECs and NAEs analyzed was observed with a
statistically significant increase in the arachidonoylethanolamide (AEA) and stearoylethanoamide
(SEA) associated with bladder cancer. Receiver operating characteristic curves built with AEA and
SEA data allowed the selection of 160 pg/mL for SEA (area under the curve (AUC) = 0.91, Selectivity
(SE) 94%, Specificity (SP) 45%) and 8 pg/mL for AEA (AUC = 0.85, SE 94%, SP 61%) as the best cut-off
values. Moreover, data from bladder cancer samples at different grades were derived from The Cancer
Genome Atlas, and the expressions of thirteen different components of the “endocannabinoidome”
were analyzed. Statistical analysis highlights significant variations in the expression of three enzymes
involved in EC and NAE turnover in bladder cancer.
Keywords: bladder cancer; endocannabinoid system; endocannabinoid quantification; biomarkers
1. Introduction
Bladder cancer is the ninth most frequently diagnosed cancer worldwide, with incidence
rates that are consistently lower in women than men. The highest rates are observed in men in
Southern and Western Europe and North America [1] with 80,470 new cases in 2019; the estimated
number of deaths in the USA was 17,670 [2]. In the European Union, the estimated number of
new bladder cancer cases in 2018 was 19,710, with an estimation of 65% deaths [3]. Bladder cancer
has the highest lifetime treatment costs per patient of all cancers, and costs have increased steadily
since 1996. Despite significant improvements in preventing disease progression and improving
survival, bladder cancer is characterized by a high rate of tumor recurrence and potential progression,
regardless of treatment with surgery, chemotherapy, or immunotherapy [4]. Patients with bladder
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cancer can be divided into patients with muscle-invasive bladder cancer (MIBC, Stages II to IV),
disease that mainly requires radical surgical treatment and chemoradiation, and patients with
the less severe non-muscle-invasive bladder cancer (NMIBC, Stage I). For NMIBC, long-term
surveillance with periodic cystoscopy is often required with heavy effects on patients’ quality of
life [5]. Moreover, the high recurrence rate and ongoing invasive monitoring requirements are
the key contributors to the economic and human toll of this disease. It has become clear that new,
less invasive diagnostic and prognostic methods for bladder cancer surveillance are needed. The great
advantage of monitoring urological tumors is the option to exploit urine samples, which are easy
to retrieve and are actually enriched in cancer-cell-derived molecules due to direct contact with
the tumor itself. The possibility of discovering novel diagnostic markers for bladder cancer in
urine could overcome the continuous, invasive monitoring of patients. The endocannabinoid
system (ECS) is an endogenous signaling system that is transiently active. The biological effects of
endocannabinoids (ECs), endogenous long-chain fatty acid derivatives able to activate the ECS,
depend on their trafficking in extracellular space and lifespan, which is limited by enzymatic
degradation. The ECS includes ECs, their specific receptors (cannabinoid receptors 1 and 2 (CB1
and CB2)) and biosynthetic (N-acyl-phosphatidylethanolamine lipase-D and diacyl glycerol lipase)
and catabolic pathways (fatty acid amide hydrolase (FAAH), monoacylglycerol lipase (MGLL),
and N-acylethanolamine acid amide hydrolase (NAAA)) [6,7]. Arachidonoylethanolamide (AEA) is
the earliest EC described and belongs to the group of N-acylethanolamides (NAEs), which comprises
other long-chain fatty acid ethanolamides and non-endocannabinoids, such as palmitoylethanolamide
(PEA) and oleoylethanolamide (OEA). PEA and OEA, although lacking affinity for CB1 and CB2,
can potentiate the effects of AEA via an “entourage effect” at its targets or compete with AEA for the
enzymes involved in its metabolism. Moreover, PEA and OEA can also activate transient receptor
potential vanilloid 1 (TRPV1) channels as well as the nuclear peroxisome proliferator-activated receptors
(PPARs). Together with the ECS, some NAEs, such as OEA and PEA, and their metabolic enzymes
and targets, constitute a large part of the “endocannabinoidome”. ECs and NAEs are a family of
lipid mediators involved in a wide range of biological effects [8]. It has been demonstrated that
the ECS is functionally expressed in the human bladder [9] and that its regulation is implicated
in lower urinary tract function and dysfunction [10]. Moreover, recent literature strongly suggests
a role for the ECS in the pathogenesis of cancer [11,12], describing the involvement of ECs and
NAEs in maintaining balance in cell proliferation. It has been shown successfully that ECs can act
by several different cellular mechanisms, including inhibition of cell proliferation, migration and
progression; inhibition of angiogenesis; and promotion of apoptosis and/or cell cycle arrest [13–16].
In addition, the EC involvement in bladder cancer proliferation and progression has been demonstrated
in ECV304 [17], RT4, RT112 [18], 5637, and HT-1376 [19] cellular models resembling different tumor
grades. Starting from this knowledge, a possible modification in ECs and NAEs levels in urine from
patients with bladder cancer can be hypothesized. Here we report for the first time the HPLC-MS/MS
quantification of seven ECs and NAEs in urine from healthy subjects and patients affected by bladder
cancer at different stages. In particular, the levels of AEA, PEA, OEA, linoleylethanolamide (LEA),
linolenoylethanolamide (LNEA), stearoylethanolamide (SEA), and eicosapentaenoylethanolamide
(EPEA) (Figure 1) were analyzed in urine of healthy subjects and bladder cancer patients with the aim
of revealing novel and possible non-invasive biomarkers for bladder cancer. Moreover, since 2005,
The Cancer Genome Atlas (TCGA) Pilot Project has generated a multi-platform molecular profile of
more than 11,000 human tumors across 33 different cancer types [20] and has collected survival data
from 11,600 patients [21], allowing the association between key genomic changes and clinical prognosis
to be analyzed. Aiming to reveal significant changes in the ECS associated with bladder cancer outcome
and progression, the expression and prognostic impact of 13 components of the “endocannabinoidome”
were explored in 404 bladder cancer samples, using high-dimensional datasets of cancer specimens
from clinical patients in The Cancer Genome Atlas.
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Figure 1. Chemical structures of endocannabinoids (ECs) and N-acylethanolamides (NAEs) analyzed 
in urine samples. 
2. Results 
2.1. EC and NAE Quantification in Urine 
PEA, SEA, OEA, AEA, LEA, LNEA, and EPEA (Figure 1), seven different ECs and NAEs, were 
quantified by HPLC-MS/MS analysis in urine samples from healthy volunteers and patients with 
bladder cancer, whose characteristics are displayed in Table 1. Caucasian patients with a diagnosis 
of primary urothelial carcinoma of the bladder were enrolled in the study. Patients with concomitant 
or previous diagnoses of prostate, renal, and upper excretory tract cancer, urinary tract infections, 
and kidney failure were excluded. Control urine samples were obtained from healthy volunteers 
without any current or previous diagnosis of cancer or other pathologies of the urinary tract. 
Table 1. Demographic and clinical–pathological characteristics of studied patients with bladder 
cancer and healthy controls. 
Variables NMIBC pTa-pT1 (n = 16) MIBC Pt2-Pt4 (n = 14) Healthy Control (n = 14) 
Age (mean ± SD, years) 65.0 ± 17.2 65.0 ± 11.4 57.2 ± 11.9 
Tumor grade 
Low grade (G1–G2) 
High grade (G2–G3) 
 
13 (81%) 
3 (19%) 
 
0 (0%) 
14 (100%) 
 
Carcinoma in situ (CIS) 
Yes 
No 
 
2 (12%) 
14 (88%) 
 
9 (64%) 
5 (36%) 
 
Lymph node involvement 
N0 
N1–3 
 
16 (100%) 
(0%) 
 
8 (57%) 
6 (43%) 
 
First episode 
Yes 
No 
 
7 (44%) 
9 (56%) 
 
3 (21%) 
11 (79%) 
 
Angioinvasion 
Yes 
No 
 
0 (100%) 
16 (0%) 
 
4 (28%) 
10 (72%) 
 
The obtained data were then normalized with creatinine content to exclude the influence of the 
urine dilution factor. As shown in Figure 2, only AEA, SEA, PEA, and LNEA quantifications gave 
reliable results. EPEA and OEA urine contents, indeed, were too low for detection and quantification, 
respectively. 
2. Results
2.1. EC and NAE Quantification in Urine
PEA, SEA, OEA, AEA, LEA, LNEA, and EPEA (Figure 1), seven different ECs and NAEs,
were quantified by HPLC-MS/MS analysis in urine samples from healthy volunteers and patients with
bladder cancer, whose characteristics are displayed in Table 1. Caucasian patients with a diagnosis of
primary urothelial carcinoma of the bladder were enrolled in the study. Patients with concomitant
or previous diagnoses of prostate, renal, and upper excretory tract cancer, urinary tract infections,
and kidney failure were excluded. Control urine samples were obtained from healthy volunteers
without any current or previous diagnosis of cancer or other pathologies of the urinary tract.
Table 1. Demographic and clinical–pathological characteristics of studied patients with bladder cancer
and healthy controls.
Variables
NMIBC
pTa-pT1
(n = 16)
MIBC
Pt2-Pt4
(n = 14)
Healthy Control
(n = 14)
Age (mean ± SD, years) 65.0 ± 17.2 65.0 ± 11.4 57.2 ± 11.9
Tumor grade
Low grade (G1–G2) 13 (81%) 0 (0%)
High grade (G2–G3) 3 (19%) 14 (100%)
Carcinoma in situ (CIS)
Yes 2 (12%) 9 (64%)
No 14 (88%) 5 (36%)
Lymph node involvement
N0 16 (100%) 8 (57%)
N1–3 (0%) 6 (43%)
First episode
Yes 7 (44%) 3 (21%)
No 9 (56%) 11 (79%)
Angioinvasion
Yes 0 (100%) 4 (28%)
No 16 (0%) 10 (72%)
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The obtained data were then normalized with creatinine content to exclude the influence of
the urine dilution factor. As shown in Figure 2, only AEA, SEA, PEA, and LNEA quantifications
gave reliable results. EPEA and OEA urine contents, indeed, were too low for detection and
quantification, respectively.
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Figure 2. Levels of the ECs and NAEs in urine samples, expressed in ng/mL: arachidonoylethanolamide
(AEA), N-palmitoylethanolamide (PEA), N-stearoylethanolamide (SEA), and N-linolenoylethanolamide
(LNEA). ECs and NAEs were quantified by HPLC-MS/MS analysis in urine samples of healthy
volunteers (CTRL) and patients with bladder cancer (Tumor). The statistical significance of differences
was evaluated by the Student’s t-Test, ** p ≤ 0.01.
LEA levels, instead, showed too much subject–subject variability to be considered. From the four
remaining ECs and NAEs, despite the increment in the four ECs and NAEs concentrations reported in
Figure 2, only AEA and SEA displayed a statistically significant increase in tumor patients’ samples
(Figure 2). When data were split between NMIBC and MIBC, although PEA and LNEA levels did
not show significant variations, again a constant increase in the concentrations of these molecules in
patients’ urine was evident (Figure 3). For compounds AEA and SEA, one-way ANOVA analysis
showed that statistically significant differences were maintained.
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Figure 3. Levels of the ECs and NAEs in urine samples, expressed in ng/mL, dividing patients
between non-muscle-invasive and muscle-invasive bladder cancer: arachidonoylethanolamide (AEA),
N-palmitoylethanolamide (PEA), N-stearoylethanolamide (SEA), and N-linolenoylethanolamide
(LNEA). ECs and NAEs were quantified by HPLC-MS/MS analy is in healthy volunteer (CTRL)
and bladder cancer pat ents with non- scle-i asi e blad er cancer (NMIBC) and muscle-invasive
bladder cancer (MIBC). T e statistical significance of diff rences was evaluated by one-way ANOVA,
with *** p ≤ 0.001.
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The diagnostic performance for the proposed biomarkers was evaluated using receiver operating
characteristic (ROC) analysis, and the obtained ROC curves, built with AEA and SEA data, are shown
in Figure 4.
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Figure 4. Univariate ROC curve analysis of AEA and SEA. Urine marker levels were assessed for their
ability to discriminate bladder cancer patients from healthy subjects.
Moreover, the data obtained from ROC analysis with AEA and SEA values are reported in Table 2.
The calculated area under the curve (AUC) values were greater or equal to 0.85 for both AEA and SEA.
The cut-off values proposed were selected to obt in the best possible val es for both sensitivity and
specificity (Table 2) and are 8 pg/mL for AEA and 160 pg/mL for SEA.
Table 2. Bladder cancer diagnosis values for AEA and SEA.
Markers Sensitivity Specificity Cut-off Likelihood AUC
AEA 94% 45% 8 pg/mL 1.76 0.85
SEA 94% 61% 160 pg/mL 2.43 0.91
2.2. The Cancer Genome Atlas Analysis
o better elucidat the role of the ECS in bladder cancer and the results obtained from urine,
we took advantage of the cohort of patients with bladder cancer available on The Cancer Genome Atlas
(TGCA) database. We analyzed the gene expression data of the “endocannabinoidome”, which include
enzymes involved in ECs synthesis (1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase
beta-1-4 (PLCB1-4), protein tyrosine phosphatase N22 (PTPN22), αβ hydrolase D4 (ABHD4),
glycerophosphodiesterase-1 (GDE1), sn1-specific diacylglycerol lipase alpha (DAGLA), sn1-specific
diacylglycerol lipase beta (DAGLB), and N-arachidonoyl-phosphatidyl-ethanolamine phospholipase
D (NAPE-PLD)) as well as those in ECs catabolism (FAAH, NAAA, and MGLL). Patients with bladder
cancer were divided into four groups based on the tumor stage (Table 3). The comparison of the four
groups showed statistically significant differences in DAGLA, NAAA, and, particularly, FAAH.
While NAAA and FAAH showed peculiar behavior going from lower to higher stages, with the
first exhibiting an increasing pattern and the second a decreasing one, a clear tendency of DAGLA was
not definite (Figure 5).
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Table 3. Gene expression of the endocannabinoid system components in bladder cancer samples from
The Cancer Genome Atlas (TGCA) dataset. 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase
beta-1-4 (PLCB1-4), N-arachidonoyl-phosphatidyl-ethanolamine phospholipase D (NAPE-PLD), protein
tyrosine phosphatase N22 (PTPN22), αβ hydrolase D4 (ABHD4), glycerophosphodiesterase-1 (GDE1),
sn1-specific diacylglycerol lipase alpha (DAGLA), sn1-specific diacylglycerol lipase beta (DAGLB),
fatty acid amide hydrolase 1 (FAAH), N-acylethanolamine acid amidase (NAAA), and monoacylglycerol
lipase (MGLL) values were reported by stage. The statistical significance of differences, highlighted in
bold, was evaluated by ANOVA. * p ≤ 0.05, *** p ≤ 0.001.
Gene Name less_than_T2a T2a T2b T3–T4 p Value
PLCB1 343.60 430.09 334.07 364.06 0.251
PLBC2 232.18 430.09 258.14 271.75 0.702
PLBC3 1986.26 2095.16 2065.71 2045.11 0.900
PLBC4 89.60 130.41 131.73 122.30 0.720
NAPE-PLD 398.99 382.45 324.87 337.41 0.085
PTPN22 42.53 43.75 71.75 67.90 0.179
ABHD4 1030.56 924.14 923.84 1055.02 0.154
GDE1 3131.74 2719.12 2513.97 2694.98 0.475
DAGLA 109.29 94.03 114.13 124.48 0.023 *
DAGLB 587.9 530.75 652.54 624.55 0.138
FAAH 886.46 612.25 650.59 577.65 1.00 × 10−4 ***
NAAA 334.28 269.56 415.36 405.78 0.012 *
MGLL 684.47 807.24 842.41 957.37 0.158
With the aim of better understanding the impact of the FAAH and NAAA expressions on bladder
cancer development, we split patients into two groups—high and low expressors of these enzymes.
The high expression of NAAA is correlated to a drastically reduced overall survival in patients with
bladder cancer, in particular in Stage II (Figure 6A,B). On the other hand, low levels of FAAH are
linked to poor prognosis (Figure 6C,D), especially at Stages II and III.
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Figure 5. Analysis of endocannabinoid system components expression in patients with bladder 
cancer. In silico gene expression analysis of DAGLA (A), NAAA (B), and FAAH (C) throughout 
bladder cancer stages from TGCA dataset. Data are expressed as reads per kilobase million (RPKM) 
and box-and-whisker plots showing minimum, 25th percentile, 50th percentile (median), 75th 
percentile, and maximum values of the percentage. The expression difference among stages was 
evaluated by performing an ANOVA test. * p < 0.5; *** p < 0.001. 
With the aim of better understanding the impact of the FAAH and NAAA expressions on 
bladder cancer development, we split patients into two groups—high and low expressors of these 
enzymes. The high expression of NAAA is correlated to a drastically reduced overall survival in 
patients with bladder cancer, in particular in Stage II (Figure 6A,B). On the other hand, low levels of 
FAAH are linked to poor prognosis (Figure 6C,D), especially at Stages II and III. 
Figure 5. Analysis of endocannabinoid system components expression in patients with bladder cancer.
In silico gene expression analysis of DAGLA (A), NAAA (B), and FAAH (C) throughout bladder
cancer stages from TGCA dataset. Data are expressed as reads per kilobase million (RPKM) and
box-and-whisker plots showing minimum, 25th percentile, 50th percentile (median), 75th percentile,
and maximum values of the percentage. The expression difference among stages was evaluated by
performing an ANOVA test. * p < 0.5; *** p < 0.001.
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Figure 6. High NAAA and low FAAH levels correlate with poor prognosis. Kaplan–Meier plots of 
patients with bladder cancer were drawn considering the high or low NAAA and FAAH gene 
expression levels on the overall population (A and C) or on the single stage (B and D). 
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cancer disease [11,12]. Considering its anti-carcinogenic activity, demonstrated in gliobastoma [23],
uterine cervix [24], and neuroblastoma, lymphoma, and breast cancer [25], the enhanced levels of AEA
in the urine of patients with bladder cancer can be due to a mobilization of the ECS to counteract cancer
cell proliferation. Of particular interest is the increase of SEA, the ethanolamide of the saturated stearic
acid, a very little studied NAEs. Although SEA cannot be considered an ECs because its activity is not
mediated by CB receptors, it can be considered an entourage compound of the ECS. Indeed, it has
been demonstrated by Maccarone and co-workers [26] that SEA is hydrolyzed by FAAH and is able to
potentiate the activity of AEA. Moreover, the SEA cannabimimetic and pro-apoptotic properties have
been demonstrated in C6 glioma cells [27] and tumoral human brain cells [28]. When the data were split
between non-muscle-invasive (Stage I) and muscle-invasive (Stages II and III) bladder cancers, all four
ECs and NAEs displayed a similar trend with an increase in ECs and NAEs concentrations and the
statistical significance was maintained for AEA and PEA, as highlighted by one-way ANOVA analysis
(Figure 3). In this case, the small number of patients (14 and 16 for the two groups, respectively) and
the variability intra-group did not allow statistical significance in the comparison of each group with
the control group to be obtained. The NMIBC group seemed to show an increase in AEA and SEA
in respect to MIBC but also variance in this group was augmented, which is in part due to a single
case that displayed quite high values (but not enough to be considered an outlier); for this reason
these results do not allow us to draw unequivocal conclusions. Together these results seem to point
out an activation of the ECS in response to bladder cancer onset, prompting us to investigate the
possibility of promoting AEA and SEA as urine biomarkers for bladder cancer. Even if the number of
bladder cancer patients (30) can be considered too small for ROC analysis, we decided to perform it
anyway and to report the obtained results in order to have a preliminary evaluation of the possibility of
proposing these two ECs as future biomarkers. Both AEA and SEA display the ability to discriminate
bladder cancer patients from healthy subjects, with an AUC value of 0.85 for AEA and 0.91 for SEA.
Selecting 8 pg/mL for AEA and 160 pg/mL for SEA as cut-off values, the sensitivities for diagnosing
bladder cancer based on the AEA and SEA levels in urine are 94% for both, and the specificities are
45% and 61%, respectively. These two cut-off values were selected to obtain good sensitivity, and we
can suppose that the low specificity could be overcome by considerably increasing the number of
patients. These results encourage us to propose AEA and SEA levels in urine as potential biomarkers
preventively examined for individuals at high risk of bladder cancer recurrence to determine the
necessity of cystoscopy examination. Additional experiments involving a great number of patients
are required to confirm our hypothesis. Moreover, a large-scale study could also reveal statistically
significant variations in the other ECs and NAEs levels. To better understand the role of ECs and NAEs
in bladder cancer, we analyzed gene expression data from TGCA database regarding the metabolic
pathway of the ECS, comprising the synthetic enzymes (PLCB1-4, PTPN22, ABHD4, GDE1, DAGLA,
DAGLB, and NAPE-PLD) and the hydrolytic ones (FAAH, NAAA, and MGLL). The division of TGCA
data into four groups, based on the tumor stage, allowed us to highlight the statistically significant
variation in the expression of only one synthetic enzyme, the sn1-specific DAGLB, which increases with
the progression of the tumor stage (from T2b to T3–T4, Figure 5). Considering the hydrolytic enzymes,
a particular behavior is shown by NAAA and FAAH with an apparent decrease in the expression of
the first at stage T2a followed by an increase from the T2b grade, while the second shows an evident
decrease from stage T2a to T3-4 of bladder cancer as reported in Figure 5. Moreover, splitting patients
into two groups with high or low expression of these two enzymes, the high expression of NAAA
correlates to drastically reduced survival, in particular at Stage II, while low levels of FAAH correlate
to poor prognosis. Taken together, these results highlight a modulation of the activity of the ECS in
bladder cancer, supporting the hypothesis of an activation of the ECS toward bladder cancer. Further
studies aimed at analyzing in depth the mechanistic aspect of the ECS activation in bladder cancer will
help us to understand the involvement of this lipid signaling system in bladder cancer.
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4. Materials and Methods
4.1. Reagents and Solvents
PEA, C16:0; SEA, C18:0; OEA, C18:1; AEA, C20:4; LEA, C18:2; LNEA, C18:3; EPEA, C20:5;
d4-SEA; and d4-LNEA were synthesized and completely characterized in our laboratories as previously
described [29–32]. HPLC grade and LC-MS grade organic solvents were purchased from Panreac
Quimica Sau (Barcelona, Spain). Acetonitrile (HPLC grade) and formic acid (used for elution of
the analytes), NaOH, and picric acid were purchased from Sigma-Aldrich (Munich, Germany).
Solid-phase extraction cartridges OASIS HBL (30 mg/mL) were purchased from Waters (Etten-Leur,
The Netherlands).
4.2. Patients Selection and Urine Collection
Thirty patients aged 40–81 years (Table 2) were enrolled in the present study. All the studies
carried out on patients’ samples were approved by the Institutional Ethical Committee (Ospedale San
Raffaele, Milan, protocol URBBAN, Rev. 2 February 2014, approval date 3 March 2014), and the specific
informed consent was obtained. All the experimental procedures involving human biological material
were carried out in compliance with the approved guidelines. Control urine samples were obtained
from healthy volunteers aged 45–59 years without any current or previous diagnoses of cancer or other
pathologies in relation to the urinary tract.
Caucasian patients aged between 40 and 81 years with a diagnosis of primary urothelial carcinoma
of the bladder were recruited. Patients with concomitant or previous diagnoses of prostate, renal and
upper excretory tract cancer, urinary tract infections, and kidney failure were excluded. Urine samples
were collected before the surgical intervention and processed soon after. The samples were centrifuged
at 300g for 5 min, aliquoted, and stored at −80 ◦C until use.
4.3. EC and NAE Quantification in Urine
ECs and NAEs were quantified on a ABSciex 5600 TripleTOF mass spectrometer (AB Sciex,
FosterCity, CA, USA) coupled with an Agilent 1200 Infinity pump LC system equipped with an Agilent
1290 Infinity autosampler (Agilent Technologies, Waldbronn, Germany) using the HPLC-MS/MS
method previously reported [32–34]. Briefly, 1.0 mL of urine was spiked with internal standard (d4-SEA
and d4-LNEA) and 800 µL of cold acetone was added for protein precipitation. After centrifugation,
the supernatants were purified by a solid-phase extraction (SPE) procedure with a manifold SPE
extractor and OASIS HBL (30 mg/mL). After conditioning of the cartridge (1.0 mL methanol/water,
60:40), the sample was loaded and the cartridge washed (1.0 mL methanol/water, 60:40). Then the
cartridge was left for 1 h to dry under vacuum, and the elution was performed with 750 µL of
acetonitrile, containing 1% of formic acid. Eluates were dried under vacuum, reconstituted in 50 µL
of acetonitrile, containing 1% of formic acid, and analyzed. Quantifications were performed using
Multiquant 1.2.1 software by AB Sciex. All extraction and purification experiments were performed in
duplicate, and all eluates were injected (20 µL) and analyzed twice; the means of the obtained values
have been used for the statistical analyses.
4.4. Creatinine Quantification in Urine
The creatinine concentration in the urine samples was determined by Jaffe’s reaction as described
in literature [22]. Briefly, the urine samples were diluted 100 times in distilled water, then 1% NaOH and
1% picric acid were added and the obtained solutions were mixed and incubated at room temperature
for 15 min; after that, the absorbance was read at 520 nm. In a typical analysis in a 96-well plate, in each
well, 100 µL of diluted urine, 25 µL of NaOH 0.25N, and 25 µL of picric acid (1% in water) were added.
Each urine was analyzed in triplicate and the mean value was used for normalization.
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4.5. The Cancer Genome Atlas Analysis
For gene expression analysis, normalized RPKM (reads per kilobase million) values were
downloaded from the Genomics Data Common Data Portal (https://portal.gdc.cancer.gov/) along
with patient clinical data. TGCA dataset includes 404 bladder cancer patients (74% male and 26%
female) with different stages of the disease as follows: less than T2a (42 patients), T2a (25 patients), T2b
(56 patients), and T3–T4 (251 patients). The vast majority of the tumors are high grade (94%), while low
grade tumors are 5%. Patients without indications about the tumor stage or grade were excluded.
ANOVA tests were performed by using the R software package (https://www.R-project.org/) [35,36].
Kaplan–Meier survival plots of bladder cancer patients with high or low FAAH and NAAA were
drawn using data from the Kaplan–Meier database available at www.kmplot.com [37].
4.6. Statistical Analysis
All urine samples (from controls and patients) were extracted in duplicate and analyzed (at least)
in duplicate; the mean calculated for each sample was used for statistical analyses. Statistical analyses
were performed with GraphPad Prism 5; the significance of the EC and NAE level variations between
the samples of the controls and the patients were assessed by the unpaired Student’s t-test. A one-way
ANOVA was applied to compare healthy controls to patients with bladder cancer divided into two
groups—NMIBC and MIBC. The diagnostic performance for each biomarker was evaluated using
receiver operating characteristic curve (ROC) analysis, reporting the area under the curve (AUC).
The significance of differences in the endocannabinoid system components expression in healthy and
bladder cancer samples were assessed by one-way ANOVA using R software.
5. Conclusions
Bladder cancer is a frequently diagnosed cancer worldwide with a high rate of recurrence linked
to significant lifetime treatment costs and long-term surveillance with invasive monitoring. Moreover,
the involvement of the ECS in urinary cancer onset and progression is well known. Considering the
urgent need of a new and non-invasive monitoring process and the advantageous option of being able
to exploit urine samples, which are directly in contact with tumor cells, we explored the possibility of
linking ECS activity alterations to bladder cancer onset.
The obtained preliminary data strongly suggest promoting ECs and NAEs, with particular
attention to AEA and SEA urine levels, as early biomarkers for bladder cancer. Moreover, statistically
significant variations in the expression of EC metabolic enzymes is linked to bladder cancer, supporting
the hypothesis of an activation of the ECS to counteract bladder cancer.
Further experiments, performed on a larger cohort of patients, are required to validate this
hypothesis and could promote ECs and NAEs as new biomarkers.
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